UALCAN

Home
Tutorial
TCGA
Proteomics
CBTN

Select cancer

Adrenocortical carcinoma

Bladder urothelial carcinoma

Brain lower grade glioma

Breast invasive carcinoma

Metastatic breast cancer

Cervical squamous cell carcinoma

Cholangiocarcinoma

Colon adenocarcinoma

Esophageal carcinoma

Glioblastoma multiforme

Head and Neck squamous cell carcinoma

Kidney Chromophobe

Kidney renal clear cell carcinoma

Kidney renal papillary cell carcinoma

Acute myeloid leukemia

Liver hepatocellular carcinoma

Lung adenocarcinoma

Lung squamous cell carcinoma

Lymphoid Neoplasm Diffuse Large B-cell Lymphoma

Ovarian serous cystadenocarcinoma

Pancreatic adenocarcinoma

Pheochromocytoma and Paraganglioma

Prostate adenocarcinoma

Metastatic prostate cancer

Rectum adenocarcinoma

Skin Cutaneous Melanoma

Stomach adenocarcinoma

Testicular Germ Cell Tumors

Thyroid carcinoma

Uterine Carcinosarcoma

Uterine Corpus Endometrial Carcinoma

TRAPPC2 expression based on

Comparison	Statistical significance
Normal-vs-Primary	3.991800E-01

Genecards
TargetScan
PubMed-Cancer
Human Protein Atlas
OpenTargets GTEx iPATH

Note Cancer stage information is not available for 2 samples.

Show statistics

Hide statistics
Comparison	Statistical significance
Normal-vs-Stage1	2.525200E-01
Normal-vs-Stage2	4.602400E-02
Normal-vs-Stage3	9.542400E-01
Normal-vs-Stage4	4.578000E-01
Stage1-vs-Stage2	2.340400E-01
Stage1-vs-Stage3	1.271190E-01
Stage1-vs-Stage4	5.363800E-02
Stage2-vs-Stage3	3.258300E-02
Stage2-vs-Stage4	1.111580E-02
Stage3-vs-Stage4	4.743400E-01

Genecards
TargetScan
PubMed-Cancer
Human Protein Atlas
OpenTargets GTEx iPATH

Note Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.

Show statistics

Hide statistics
Comparison	Statistical significance
Normal-vs-Caucasian	5.676600E-01
Normal-vs-AfricanAmerican	9.043400E-01
Normal-vs-Asian	5.721800E-02
Caucasian-vs-AfricanAmerican	7.861600E-01
Caucasian-vs-Asian	8.797700E-02
AfricanAmerican-vs-Asian	1.932040E-01

Genecards
TargetScan
PubMed-Cancer
Human Protein Atlas
OpenTargets GTEx iPATH

Show statistics

Hide statistics
Comparison	Statistical significance
Normal-vs-Male	2.977600E-03
Normal-vs-Female	3.086500E-02
Male-vs-Female	1.65345515057425E-12

Genecards
TargetScan
PubMed-Cancer
Human Protein Atlas
OpenTargets GTEx iPATH

Note Seventeen samples from patient below 21 years not considered in above plot.

Show statistics

Hide statistics
Comparison	Statistical significance
Normal-vs-Age(21-40Yrs)	2.419200E-01
Normal-vs-Age(41-60Yrs)	4.076200E-01
Normal-vs-Age(61-80Yrs)	6.802800E-01
Normal-vs-Age(81-100Yrs)	1.133600E-01
Age(21-40Yrs)-vs-Age(41-60Yrs)	6.891800E-01
Age(21-40Yrs)-vs-Age(61-80Yrs)	4.412000E-01
Age(21-40Yrs)-vs-Age(81-100Yrs)	7.733800E-02
Age(41-60Yrs)-vs-Age(61-80Yrs)	6.349400E-01
Age(41-60Yrs)-vs-Age(81-100Yrs)	7.312300E-02
Age(61-80Yrs)-vs-Age(81-100Yrs)	1.007750E-01

Genecards
TargetScan
PubMed-Cancer
Human Protein Atlas
OpenTargets GTEx iPATH

Show statistics

Hide statistics
Comparison	Statistical significance
Classical-VS-Tall	4.615500E-03
Classical-VS-Follicular	7.824500E-02
Classical-VS-Other	5.486400E-01
Classical-VS-Normal	3.053600E-01
Tall-VS-Follicular	9.7979999999942E-05
Tall-VS-Other	3.131800E-01
Tall-VS-Normal	5.678000E-02
Follicular-VS-Other	2.898600E-01
Follicular-VS-Normal	2.616200E-02
Other-VS-Normal	8.484800E-01

Genecards
TargetScan
PubMed-Cancer
Human Protein Atlas
OpenTargets GTEx iPATH

Note Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.

pathologic_N descriptions
N0	No regional lymph node metastasis	N1	Metastases in 1 to 3 axillary lymph nodes
N2	Metastases in 4 to 9 axillary lymph nodes	N3	Metastases in 10 or more axillary lymph nodes

Show statistics

Hide statistics
Comparison	Statistical significance
Normal-vs-N0	1.016780E-01
Normal-vs-N1	8.004600E-01
N0-vs-N1	2.761800E-01

Genecards
TargetScan
PubMed-Cancer
Human Protein Atlas
OpenTargets GTEx iPATH

Please send your queries/feedback to ualcanask at gmail dot com

Contact UAB
|
Privacy
|
Terms of Use
|
© 2022 The University of Alabama at Birmingham

UAB is an Equal Opportunity/Affirmative Action Employer committed to fostering a diverse, equitable and family-friendly environment in which all faculty and staff can excel and achieve work/life balance irrespective of race, national origin, age, genetic or family medical history, gender, faith, gender identity and expression as well as sexual orientation. UAB also encourages applications from individuals with disabilities and veterans.